Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Daniel Olson

Podiatrist, Foot & Ankle Surgery Erie, PA Doctor of Podiatric Medicine

NPI 1255395224 CMS profile 283931

3850 Walker Blvd, Erie, PA 16509

Open in the dashboard

General payments

$8,165

266 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Daniel Olson of Erie, PA is reported in the CMS Open Payments database as having received $8,165 across 266 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,085 39
2024 General $534 20
2023 General $693 17
2022 General $909 33
2021 General $1,427 61
2020 General $514 38
2019 General $3,003 58

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Olson
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Daniel Olson were reported at $1,085. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Daniel Olson Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $3,003 $389 $118–$1,406 $163
2020 $514 $191 $62–$691 $114
2021 $1,427 $329 $104–$1,341 $132
2022 $909 $419 $125–$1,611 $149
2023 $693 $377 $128–$1,164 $160
2024 $534 $394 $134–$1,168 $164
2025 $1,085 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Smith+Nephew, Inc. $2,352 133 payments
  2. Organogenesis Inc. $1,392 33 payments
  3. Wright Medical Technology, Inc. $1,057 7 payments
  4. Mid-Atlantic Surgical Systems, LLC $812 2 payments
  5. Arthrex, Inc. $516 5 payments
  6. Horizon Therapeutics plc $254 17 payments
  7. Medtronic, Inc. $229 2 payments
  8. Paratek Pharmaceuticals, Inc. $205 9 payments
  9. Bioventus LLC $197 11 payments
  10. Boston Scientific Corporation $178 2 payments
  11. Other $972 45 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,870 257 payments
  2. Travel and Lodging $1,802 7 payments
  3. Education $493 2 payments
Products named General payments · program years 2019–2025
  1. PROstep $1,057 7 payments
  2. GRAFIX PL Other Advanced Wound Management $1,021 51 payments
  3. Puraply $722 17 payments
  4. PURAPLY WOUND MATRIX $385 5 payments
  5. APLIGRAF $378 4 payments
  6. Affinity $362 3 payments
  7. GRAFIX PL Other Advanced Wound Management $353 26 payments
  8. STRAVIX PL $310 4 payments
  9. NUZYRA $205 9 payments
  10. COLLAGENASE SANTYL $167 11 payments
  11. Other $3,442 159 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

181

Median for Podiatry: 160

Drug cost

$1,593

Median for Podiatry: $2,368

Branded share of claims

20.4%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ketoconazole Generic 13 $497
Pregabalin Generic 22 $346
Gabapentin Generic 21 $151
Doxycycline Hyclate Generic 15 $137
Mupirocin Generic 13 $126
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 22 $110
Allopurinol Generic 37 $106
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 15 $59
Celecoxib Generic 23 $59

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 70 billing codes

Paid by Medicare

$213,944

Of which drugs: $121,509

Medicare patients

310

Average age 78

Services billed

5,800

207 women, 103 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 63%
Diabetes 41%
Ischemic heart disease 33%
Chronic kidney disease 30%
Atrial fibrillation 27%
Depression 26%
Heart failure 24%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 12 78 $58

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUZYRA
  • Paratek Pharmaceuticals, Inc. $170
$170 — —
Qutenza
  • Averitas Pharma Inc. $21
$21 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

266 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot & Ankle Surgery in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record